BG63544B1 - Дихидратни соли на 5-(2-(4-(1,2-бензизотиазол-3- ил)-1-пиперазинил)-етил)-6-хлоро-1,3-дихидро-2(1н)-индол- 2-он (= ципразидон), мезилат, получаванетоим и използуването им като антагонист на допаминd2 - Google Patents

Дихидратни соли на 5-(2-(4-(1,2-бензизотиазол-3- ил)-1-пиперазинил)-етил)-6-хлоро-1,3-дихидро-2(1н)-индол- 2-он (= ципразидон), мезилат, получаванетоим и използуването им като антагонист на допаминd2 Download PDF

Info

Publication number
BG63544B1
BG63544B1 BG102892A BG10289298A BG63544B1 BG 63544 B1 BG63544 B1 BG 63544B1 BG 102892 A BG102892 A BG 102892A BG 10289298 A BG10289298 A BG 10289298A BG 63544 B1 BG63544 B1 BG 63544B1
Authority
BG
Bulgaria
Prior art keywords
common
mesylate
benzisothiazol
chloro
ethyl
Prior art date
Application number
BG102892A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102892A (en
Inventor
Frank BUSCH
Carol ROSE
Russell SHINE
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG102892A publication Critical patent/BG102892A/xx
Publication of BG63544B1 publication Critical patent/BG63544B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
BG102892A 1996-05-07 1998-11-03 Дихидратни соли на 5-(2-(4-(1,2-бензизотиазол-3- ил)-1-пиперазинил)-етил)-6-хлоро-1,3-дихидро-2(1н)-индол- 2-он (= ципразидон), мезилат, получаванетоим и използуването им като антагонист на допаминd2 BG63544B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07
PCT/IB1997/000393 WO1997042191A1 (en) 1996-05-07 1997-04-10 Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist

Publications (2)

Publication Number Publication Date
BG102892A BG102892A (en) 1999-09-30
BG63544B1 true BG63544B1 (bg) 2002-04-30

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102892A BG63544B1 (bg) 1996-05-07 1998-11-03 Дихидратни соли на 5-(2-(4-(1,2-бензизотиазол-3- ил)-1-пиперазинил)-етил)-6-хлоро-1,3-дихидро-2(1н)-индол- 2-он (= ципразидон), мезилат, получаванетоим и използуването им като антагонист на допаминd2

Country Status (41)

Country Link
US (1) US6245765B1 (cs)
EP (1) EP0918772B1 (cs)
JP (1) JP3494659B2 (cs)
KR (1) KR100333215B1 (cs)
CN (1) CN1091769C (cs)
AP (1) AP765A (cs)
AR (1) AR007004A1 (cs)
AT (1) ATE278689T1 (cs)
AU (1) AU731267B2 (cs)
BG (1) BG63544B1 (cs)
BR (1) BR9709889A (cs)
CA (1) CA2252898C (cs)
CO (1) CO4940466A1 (cs)
CZ (1) CZ289215B6 (cs)
DE (1) DE69731094T2 (cs)
DK (1) DK0918772T3 (cs)
DZ (1) DZ2222A1 (cs)
EA (1) EA001190B1 (cs)
EG (1) EG24076A (cs)
ES (1) ES2229342T3 (cs)
GT (1) GT199700052A (cs)
HK (1) HK1017892A1 (cs)
HR (1) HRP970236B1 (cs)
ID (1) ID16867A (cs)
IL (1) IL126591A (cs)
IS (1) IS2080B (cs)
MA (1) MA24171A1 (cs)
MY (1) MY119997A (cs)
NO (1) NO312514B1 (cs)
NZ (1) NZ332218A (cs)
OA (1) OA10909A (cs)
PL (1) PL188330B1 (cs)
PT (1) PT918772E (cs)
SI (1) SI0918772T1 (cs)
SK (1) SK282837B6 (cs)
TN (1) TNSN97074A1 (cs)
TR (1) TR199802240T2 (cs)
TW (1) TW491847B (cs)
UA (1) UA46840C2 (cs)
WO (1) WO1997042191A1 (cs)
ZA (1) ZA973876B (cs)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EE200200670A (et) * 2000-06-02 2004-08-16 Pfizer Products Inc. S-metüüldihüdroziprasidoon psühhiaatriliste ja silmahaiguste raviks
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
BRPI0410271A (pt) * 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
WO2005016325A2 (en) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
BRPI0518187A (pt) * 2004-11-16 2008-11-04 Elan Pharma Int Ltd formulações de olanzapina em nanopartìcula injetáveis
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
EP1742943A1 (en) * 2005-02-11 2007-01-17 Teva Pharmaceutical Industries Ltd Process of preparing ziprasidone mesylate
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
JP2010527925A (ja) * 2007-05-18 2010-08-19 サイドース・エルエルシー ジプラシドン製剤
JP2011526881A (ja) * 2008-06-25 2011-10-20 ファイザー・インク ジアリール化合物およびそれらの使用
US9469630B2 (en) * 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
SI0904273T1 (en) 1996-05-07 2003-08-31 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist

Also Published As

Publication number Publication date
AP765A (en) 1999-09-17
GT199700052A (es) 2001-08-29
AU2174797A (en) 1997-11-26
NO985194L (no) 1998-11-06
AR007004A1 (es) 1999-10-13
AP9700976A0 (en) 1997-07-31
EP0918772B1 (en) 2004-10-06
IL126591A (en) 2001-11-25
JP3494659B2 (ja) 2004-02-09
EG24076A (en) 2008-05-11
BG102892A (en) 1999-09-30
DK0918772T3 (da) 2005-01-10
DE69731094T2 (de) 2006-02-23
NO312514B1 (no) 2002-05-21
ES2229342T3 (es) 2005-04-16
CZ289215B6 (cs) 2001-12-12
CA2252898C (en) 2003-04-08
TNSN97074A1 (fr) 2005-03-15
ZA973876B (en) 1998-11-06
OA10909A (en) 2001-10-26
EP0918772A1 (en) 1999-06-02
IS4874A (is) 1998-10-20
HK1017892A1 (en) 1999-12-03
NO985194D0 (no) 1998-11-06
JPH11509867A (ja) 1999-08-31
PT918772E (pt) 2004-12-31
US6245765B1 (en) 2001-06-12
SK282837B6 (sk) 2002-12-03
CO4940466A1 (es) 2000-07-24
HRP970236A2 (en) 1998-06-30
UA46840C2 (uk) 2002-06-17
SI0918772T1 (en) 2005-02-28
PL188330B1 (pl) 2005-01-31
MA24171A1 (fr) 1997-12-31
DZ2222A1 (fr) 2002-12-03
CA2252898A1 (en) 1997-11-13
CN1216991A (zh) 1999-05-19
KR100333215B1 (ko) 2002-06-20
WO1997042191A1 (en) 1997-11-13
IL126591A0 (en) 1999-08-17
MY119997A (en) 2005-08-30
EA001190B1 (ru) 2000-12-25
TW491847B (en) 2002-06-21
CN1091769C (zh) 2002-10-02
ATE278689T1 (de) 2004-10-15
HRP970236B1 (en) 2002-12-31
NZ332218A (en) 2005-02-25
BR9709889A (pt) 1999-08-10
PL329884A1 (en) 1999-04-12
IS2080B (is) 2006-02-15
DE69731094D1 (de) 2004-11-11
CZ349398A3 (cs) 1999-09-15
AU731267B2 (en) 2001-03-29
ID16867A (id) 1997-11-20
SK150898A3 (en) 2000-02-14
EA199800912A1 (ru) 1999-04-29
KR20000010824A (ko) 2000-02-25
TR199802240T2 (cs) 1999-02-22

Similar Documents

Publication Publication Date Title
BG63544B1 (bg) Дихидратни соли на 5-(2-(4-(1,2-бензизотиазол-3- ил)-1-пиперазинил)-етил)-6-хлоро-1,3-дихидро-2(1н)-индол- 2-он (= ципразидон), мезилат, получаванетоим и използуването им като антагонист на допаминd2
AP838A (en) Mesylate trihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-y1)-1-piperaziny1)-ethy1) -6-chloro-1,3-dihydro-2h-indol-2-one.
KR0163186B1 (ko) (1,2,3,4-테트라하이드로-9-아크리딘이미노)사이클로헥산 카복실산 및 관련 화합물, 이들의 제조방법 및 약제로서의 용도
PL185709B1 (pl) Nowy monohydrat polimorfu II 6-N-(L-Ala-L-Ala)-trowafloksacyny i środek farmaceutyczny
MXPA98009242A (en) Salt mesylate trihydrate 5 - (- 2- (4- (1,2-benzoisotiazol-3-il) -1-piperazinil) ethyl) -6-chlorine-1,3-dihydro-2h-indol-2-
NZ508304A (en) Mesylate dihydrate salt of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one ( ziprasidone) useful as dopamine D2 antagonist